With the advent and increased prevalence of predictive genetic tests (PGTs), individuals now have the option to investigate their future risk of developing certain diseases, including Alzheimer‘s disease (AD). Even

though genetic testing for AD is only recommended in certain cases, the use of PGTS is almost certain to increase as technology and genetic marker identification continues to advance. Thus, aligning the clinical practice

of using predictive genetic testing for Alzheimer‘s disease with consumer values and preferences is important in

determining under what circumstances consumers would want to take a PGT for Alzheimer‘s. However, little is known about consumer preferences for genetic Alzheimer‘s disease (AD) testing. Therefore, this study was conducted to elicit societal preferences and perceived values placed on predictive AD genetic tests by combining rating-based conjoint and open-ended contingent valuation in order to answer what attributes consumers value most when deciding to take a predictive genetic test for a disease with no cure.